Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 20/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 13/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 6/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 1.00 |
| ▸ | KIT | P10721 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vimseltinib SCHEMBL16047448 | 1.00 | CSF1R (1.00) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| Vimseltinib SCHEMBL31615255 | 0.99 | CSF1R (0.98) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL31741098 | 0.90 | CSF1R (0.82) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL16046817 | 0.89 | CSF1R (0.80) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL25909908 | 0.89 | CSF1R (0.79) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL16046264 | 0.88 | CSF1R (1.00) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL31741155 | 0.88 | CSF1R (0.78) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL25909923 | 0.86 | CSF1R (0.76) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL16048025 | 0.86 | CSF1R (0.76) | CSF1RPDGFRAPDGFRBFLT3KIT | |
| SCHEMBL25909802 | 0.86 | CSF1R (0.76) | CSF1RPDGFRAPDGFRBFLT3KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103452-A1 | SOLID STATE FORMS OF A KINASE INHIBITOR | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260078107-A1 | CSF-1R INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260048052-A1 | METHODS OF TREATING TENOSYNOVIAL GIANT CELL TUMORS | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12528787-B2 | Solid state forms of a kinase inhibitor | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250243182-A1 | SOLID STATE FORMS OF A KINASE INHIBITOR | DECIPHERA PHARMACEUTICALS, LLC | 2025-07-31 | — | — | US | disclosed |
| US-20250206720-A1 | SOLID FORMS OF AN ULK INHIBITOR | DECIPHERA PHARMACEUTICALS, LLC | 2025-06-26 | — | — | US | disclosed |
| US-20250205236-A1 | FORMULATIONS OF VIMSELTINIB | DECIPHERA PHARMACEUTICALS, LLC | 2025-06-26 | — | — | US | disclosed |
| WO-2025122952-A1 | FORMULATIONS OF VIMSELTINIB | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025122942-A1 | SOLID STATE FORMS OF A KINASE INHIBITOR | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025096349-A1 | METHODS OF TREATING TENOSYNOVIAL GIANT CELL TUMORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025065747-A1 | APPLICATION OF CSF1R INHIBITOR IN PREPARATION OF NK/T CELL LYMPHOMA TREATMENT DRUG | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2025-04-03 | — | — | WO | disclosed |
| CN-117427166-B | Application of CSF1R inhibitor in preparation of NK/T cell lymphoma therapeutic drug | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2024-09-10 | — | — | CN | disclosed |
| CN-116283919-A | Novel crystal form of Vimseltinib and preparation method thereof | 上海皓元医药股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243182-A1 | SOLID STATE FORMS OF A KINASE INHIBITOR | MAP3K19, MAP3K20, MAP3K1 | CSF1R 1415/4885PDGFRA 744/4885PDGFRB 732/4885 |
| US-20250206720-A1 | SOLID FORMS OF AN ULK INHIBITOR | ULK2, ULK1, ULK3 | CSF1R 2918/4885PDGFRA 2951/4885PDGFRB 2583/4885 |
| US-20260103452-A1 | SOLID STATE FORMS OF A KINASE INHIBITOR | CSF1R, FLT3, CSF3R | CSF1R 1/4885PDGFRA 45/4885PDGFRB 35/4885 |
| US-12528787-B2 | Solid state forms of a kinase inhibitor | CSF1R, FLT3, CSF3R | CSF1R 1/4885PDGFRA 80/4885PDGFRB 53/4885 |
| US-20260048052-A1 | METHODS OF TREATING TENOSYNOVIAL GIANT CELL TUMORS | CSF1R, CSF3R, FLT1 | CSF1R 1/4885PDGFRA 75/4885PDGFRB 83/4885 |
| US-20260078107-A1 | CSF-1R INHIBITORS AND METHODS OF USE THEREOF | CSF1R, CSF3R, FLT3 | CSF1R 1/4885PDGFRA 123/4885PDGFRB 100/4885 |
| US-20250205236-A1 | FORMULATIONS OF VIMSELTINIB | KDR, VIM, UGT1A7 | CSF1R 187/4885PDGFRA 14/4885PDGFRB 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.